WO2023142309A1 - 抗tslp纳米抗体及其应用 - Google Patents
抗tslp纳米抗体及其应用 Download PDFInfo
- Publication number
- WO2023142309A1 WO2023142309A1 PCT/CN2022/093166 CN2022093166W WO2023142309A1 WO 2023142309 A1 WO2023142309 A1 WO 2023142309A1 CN 2022093166 W CN2022093166 W CN 2022093166W WO 2023142309 A1 WO2023142309 A1 WO 2023142309A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tslp
- seq
- antibody
- nanobody
- present
- Prior art date
Links
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims abstract description 82
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims abstract description 15
- 239000013604 expression vector Substances 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 238000001514 detection method Methods 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 229940127121 immunoconjugate Drugs 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 22
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- 108091033319 polynucleotide Proteins 0.000 claims description 19
- 102000040430 polynucleotide Human genes 0.000 claims description 19
- 239000002157 polynucleotide Substances 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 14
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 14
- 102000004127 Cytokines Human genes 0.000 claims description 13
- 108090000695 Cytokines Proteins 0.000 claims description 13
- 231100000765 toxin Toxicity 0.000 claims description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 8
- 239000003053 toxin Substances 0.000 claims description 8
- 108700012359 toxins Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 230000008878 coupling Effects 0.000 claims description 7
- 238000010168 coupling process Methods 0.000 claims description 7
- 238000005859 coupling reaction Methods 0.000 claims description 7
- 239000002872 contrast media Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000010931 gold Substances 0.000 claims description 4
- 229910052737 gold Inorganic materials 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 239000002073 nanorod Substances 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 3
- 108090000565 Capsid Proteins Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000002331 protein detection Methods 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 abstract description 22
- 238000000855 fermentation Methods 0.000 abstract description 8
- 230000004151 fermentation Effects 0.000 abstract description 8
- 241000235058 Komagataella pastoris Species 0.000 abstract description 7
- 108091026890 Coding region Proteins 0.000 abstract description 5
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 abstract description 2
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 abstract 1
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 description 73
- 210000004027 cell Anatomy 0.000 description 53
- 102000004196 processed proteins & peptides Human genes 0.000 description 32
- 108090000765 processed proteins & peptides Proteins 0.000 description 32
- 229920001184 polypeptide Polymers 0.000 description 30
- 239000012634 fragment Substances 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 229950008998 tezepelumab Drugs 0.000 description 15
- 230000027455 binding Effects 0.000 description 13
- 238000009739 binding Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 208000006673 asthma Diseases 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 208000026278 immune system disease Diseases 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000045535 human TSLP Human genes 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010075254 C-Peptide Proteins 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 4
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 4
- 101710130607 Valacyclovir hydrolase Proteins 0.000 description 4
- 102100025139 Valacyclovir hydrolase Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- -1 Fe-59 Chemical compound 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000037883 airway inflammation Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 229960005501 duocarmycin Drugs 0.000 description 3
- 229930184221 duocarmycin Natural products 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- 206010016946 Food allergy Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 101710182532 Toxin a Proteins 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
- 239000012526 feed medium Substances 0.000 description 2
- 235000020932 food allergy Nutrition 0.000 description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 208000015768 polyposis Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 1
- LGNCNVVZCUVPOT-FUVGGWJZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LGNCNVVZCUVPOT-FUVGGWJZSA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 1
- SRNFODIJXVPXHO-FSJWMSIRSA-N (4r,4ar,5'r,7r,8r,8as)-5'-(furan-3-yl)-4,7-dimethylspiro[1,3,4,4a,5,6,7,8a-octahydronaphthalene-8,3'-oxolane]-2,2'-dione Chemical compound C=1([C@H]2C[C@@]3(C(O2)=O)[C@H](C)CC[C@H]2[C@@H]3CC(=O)C[C@H]2C)C=COC=1 SRNFODIJXVPXHO-FSJWMSIRSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- VGGWNGWXGFWLRK-UHFFFAOYSA-N 8,9-dihydro-1H-[1,3]oxazolo[4,5-i][1,2]benzodiazepine Chemical class C1=CC=NNC2=C(OCN3)C3=CC=C21 VGGWNGWXGFWLRK-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
- 208000037874 Asthma exacerbation Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282828 Camelus bactrianus Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 102000003826 Chemokine CCL17 Human genes 0.000 description 1
- 108010082169 Chemokine CCL17 Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- SRNFODIJXVPXHO-UHFFFAOYSA-N Crotonin Natural products CC1CC(=O)CC2C1CCC(C)C2(C(O1)=O)CC1C=1C=COC=1 SRNFODIJXVPXHO-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 description 1
- 101000960936 Homo sapiens Interleukin-5 receptor subunit alpha Proteins 0.000 description 1
- 102000039990 IL-2 family Human genes 0.000 description 1
- 108091069192 IL-2 family Proteins 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 1
- 102100039881 Interleukin-5 receptor subunit alpha Human genes 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000956432 Mus musculus Cytokine receptor-like factor 2 Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- WEMYTDDMDBLPMI-DKIMLUQUSA-N Phe-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N WEMYTDDMDBLPMI-DKIMLUQUSA-N 0.000 description 1
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 1
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 108010082017 alpha chain interleukin-7 receptor Proteins 0.000 description 1
- 150000003862 amino acid derivatives Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229950000321 benralizumab Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 108010083912 bleomycin N-acetyltransferase Proteins 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000007524 negative regulation of DNA replication Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- IFOHPTVCEBWEEQ-UHFFFAOYSA-N pyrrolo[2,3-i][1,4]benzodiazepine Chemical class N1=CC=NC2=C3C=CN=C3C=CC2=C1 IFOHPTVCEBWEEQ-UHFFFAOYSA-N 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 108091052247 type I cytokine receptor family Proteins 0.000 description 1
- 102000042286 type I cytokine receptor family Human genes 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5418—IL-7
Definitions
- the present invention relates to the field of biomedicine or biopharmaceutical technology, and more specifically relates to anti-TSLP nanobody and its application.
- Antibody drugs used for the treatment of severe asthma mostly target IgE (omalizumab), IL5 (mepolizumab, relizumab), IL5R (benralizumab), IL4R in the Th2 pathway (Dupilumab), etc. All the above drugs have a good control effect on hypereosinophilic asthma, and they are all treated by subcutaneous or intravenous injection.
- Thymic stromal lymphopoietin is a short-chain cytokine with a four-helix bundle structure and belongs to the IL-2 cytokine family.
- TSLP is an epithelial cytokine produced in response to pro-inflammatory stimuli, such as pulmonary allergens, viruses, and other pathogens, and plays a key role in the initiation and persistence of airway inflammation.
- TSLP drives the release of downstream Th2 cytokines, including IL-4, IL-5, and IL-13, leading to inflammation and asthma symptoms.
- Th2 cytokines including IL-4, IL-5, and IL-13, leading to inflammation and asthma symptoms.
- TSLP also activates various cell types involved in non-Th2-driven inflammation.
- TSLP's early upstream activity in the inflammatory cascade has been identified as a potential target in a broad population of asthmatic patients.
- Blocking TSLP prevents immune cells from releasing pro-inflammatory cytokines, thereby preventing asthma exacerbations, improving asthma control, and related diseases such as COPD.
- Nanobody that is, heavy chain nanobody VHH (variable domain of heavy chain of heavy-chain antibody) - there is a heavy-chain antibody (heavy-chain antibody, HCAb) that naturally lacks light chains in camels, and its clone Nanobodies, which are composed of only one heavy chain variable region, are currently available as the smallest unit of stable antigen-binding with complete functions. Nanobodies have the characteristics of high stability, good water solubility, simple humanization, high targeting, and strong penetrability. They play a huge role beyond imagination in immune experiments, diagnosis, and treatment. Nanobodies are gradually becoming an emerging force in the new generation of antibody therapy.
- the purpose of the present invention is to provide a kind of anti-TSLP nanobody with better blocking activity, better clinical efficacy and easy production.
- an anti-TSLP Nanobody is provided, and the CDR region of the VHH chain in the Nanobody is one or more selected from the group consisting of:
- the CDR1, CDR2 and CDR3 are separated by the framework regions FR1, FR2, FR3 and FR4 of the VHH chain.
- the VHH chain further includes a framework region FR, and the framework region FR is one or more selected from the following group:
- the CDR region of the VHH chain of the Nanobody comprises at least 80% of any of SEQ ID NO:1-3, SEQ ID NO:14-16, SEQ ID NO:27-29, Amino acid sequences with at least 90%, more preferably at least 95%, even more preferably at least 99% sequence similarity are preferred.
- the amino acid sequence of the CDR region of the VHH chain of the Nanobody comprises a or multiple amino acid substitutions, preferably conservative amino acid substitutions.
- any amino acid sequence in the above amino acid sequence also includes at least one (such as 1-3, preferably 1-2, more preferably 1) amino acid derivative sequence that can retain the specific binding ability to TSLP.
- the Nanobody can specifically bind TSLP.
- the nanobody can effectively block the interaction between TSLP and TSLPR.
- the TSLP is human or non-human mammalian TSLP.
- the TSLP is the TSLP of human, mouse, rat, or non-human primate (such as monkey).
- the nanobodies include humanized antibodies, camelid antibodies, and chimeric antibodies.
- amino acid sequence of the VHH chain of the Nanobody is selected from the group consisting of SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO: 34. SEQ ID NO: 38, or a combination thereof.
- the anti-TSLP nanobody includes a monomer, a bivalent body (bivalent antibody), a tetravalent body (tetravalent antibody), and/or a multivalent body (multivalent antibody).
- the anti-TSLP nanobody comprises one or more nanobodies such as SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 34 or The VHH chain of the amino acid sequence shown in SEQ ID NO:38.
- the anti-TSLP nanobody comprises two compounds having such as SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 34, SEQ ID The VHH chain of the amino acid sequence shown in NO:38.
- VHH chains are linked by linking peptides.
- sequence of the connecting peptide is: GGGGSGGGGSGGGGSGGGGS.
- the second aspect of the present invention provides an anti-TSLP antibody, which is an antibody against TSLP epitopes, and has the anti-TSLP nanobody described in the first aspect of the present invention.
- the anti-TSLP antibody includes one or more anti-TSLP nanobodies.
- the anti-TSLP antibody includes a monomer, a bivalent body (bivalent antibody), a tetravalent body (tetravalent antibody), and/or a multivalent body (multivalent antibody).
- the anti-TSLP antibody includes one or more antibodies having such as SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 34 or SEQ ID NO: 34 or SEQ ID NO: The VHH chain of the amino acid sequence shown in ID NO:38.
- the anti-TSLP antibody comprises two antibodies having such as SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 34 or SEQ ID NO : VHH chain of the amino acid sequence shown in 38.
- the antibody can specifically bind TSLP.
- the antibody can specifically target the TSLP protein with the correct spatial structure.
- the antibody can effectively block the interaction between TSLP and TSLPR.
- the affinity (KD value) of the antibody to TSLP is less than 3.77nM.
- the antibody has good TSLP/TSLPR blocking activity, and the blocking activity is significantly better than that of the control antibody Tezepelumab, wherein the control antibody Tezepelumab is obtained from AstraZeneca or Amgen )company.
- the antibody can effectively inhibit the proliferation of BaF3/TSLPR-IL7R cells, and its inhibitory activity is better than that of the control antibody Tezepelumab.
- the antibody is a Nanobody.
- the third aspect of the present invention provides a polynucleotide encoding a protein selected from the group consisting of the anti-TSLP nanobody described in the first aspect of the present invention or the anti-TSLP antibody described in the second aspect of the present invention .
- polynucleotides are in combination.
- polynucleotide sequence comprises one or more of the sequences shown in SEQ ID NO: 9, 13, 22, 26, 35 or 39.
- the polynucleotide includes RNA, DNA or cDNA.
- the fourth aspect of the present invention provides an expression vector, which contains the polynucleotide described in the third aspect of the present invention.
- the expression vector is selected from the group consisting of DNA, RNA, viral vector, plasmid, transposon, other gene transfer systems, or combinations thereof.
- the expression vector includes a viral vector, such as lentivirus, adenovirus, AAV virus, and retrovirus.
- the fifth aspect of the present invention provides a host cell containing the expression vector of the fourth aspect of the present invention, or the polynucleotide of the third aspect of the present invention integrated in its genome.
- the host cells include prokaryotic cells or eukaryotic cells.
- the host cell is selected from the group consisting of Escherichia coli, yeast cells, mammalian cells, phage, or combinations thereof.
- the prokaryotic cells are selected from the group consisting of Escherichia coli, Bacillus subtilis, lactic acid bacteria, Streptomyces, Proteus mirabilis, or combinations thereof.
- the eukaryotic cells are selected from the group consisting of Pichia pastoris, Saccharomyces cerevisiae, fission yeast, Trichoderma, or combinations thereof.
- the host cell is Pichia pastoris.
- the sixth aspect of the present invention provides a method of producing anti-TSLP nanobody, comprising the steps of:
- step (c) Optionally, purifying and/or modifying the anti-TSLP Nanobody obtained in step (b).
- the seventh aspect of the present invention provides an immunoconjugate comprising:
- a coupling moiety selected from the group consisting of detectable labels, drugs, toxins, cytokines, radionuclides, enzymes, gold nanoparticles/nanorods, nanomagnetic particles, viral coat proteins or VLPs, or combinations thereof .
- the radionuclides include:
- isotopes for diagnosis are selected from the group consisting of Tc-99m, Ga-68, F-18, I-123, I-125, I-131, In-111, Ga-67, Cu-64, Zr-89, C-11, Lu-177, Re-188, or combinations thereof; and/or
- the isotope for treatment is selected from the group consisting of Lu-177, Y-90, Ac-225, As-211, Bi-212, Bi-213, Cs-137, Cr-51, Co-60, Dy-165, Er-169, Fm-255, Au-198, Ho-166, I-125, I-131, Ir-192, Fe-59, Pb-212, Mo-99, Pd- 103, P-32, K-42, Re-186, Re-188, Sm-153, Ra223, Ru-106, Na24, Sr89, Tb-149, Th-227, Xe-133, Yb-169, Yb- 177, or a combination thereof.
- the coupling moiety is a drug or a toxin.
- the drug is a cytotoxic drug.
- the cytotoxic drugs are selected from the group consisting of anti-tubulin drugs, DNA minor groove binding agents, DNA replication inhibitors, alkylating agents, antibiotics, folic acid antagonists, antimetabolites, chemotherapy A sensitizer, a topoisomerase inhibitor, a vinca alkaloid, or a combination thereof.
- examples of particularly useful cytotoxic drugs include, for example, DNA minor groove binding agents, DNA alkylating agents, and tubulin inhibitors
- typical cytotoxic drugs include, for example, auristatin ( auristatins, camptothecins, duocarmycins/duocarmycins, etoposides, maytansines, and maytansinoids (such as DM1 and DM4 ), taxanes, benzodiazepines, or benzodiazepine containing drugs (such as pyrrolo[1,4]benzodiazepines (PBDs), indole Indolinobenzodiazepines and oxazolidinobenzodiazepines), vinca alkaloids, or combinations thereof.
- auristatin auristatins, camptothecins, duocarmycins/duocarmycins, etoposides
- maytansines such as DM1 and DM4
- taxanes such as benzodiazepines, or benz
- the toxin is selected from the group consisting of auristatins (for example, auristatin E, auristatin F, MMAE, and MMAF), aureomycin, maytansinol, ricin, grate Anesthetic toxin A-chain, combretastatin, duocarmycin, dolastatin, doxorubicin, daunorubicin, paclitaxel, cisplatin, cc1065, ethidium bromide, mitomycin, etoposide, Tenoposide (tenoposide), vincristine, vinblastine, colchicine, dihydroxyanthraxin diketone, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, acacia Toxin, abrin toxin A chain, lotus root toxin A chain, ⁇ -sarcinia, gelonin, mitogellin
- the coupling moiety is a detectable label.
- the coupling moiety is selected from the group consisting of fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (computer X-ray tomography) contrast agents, or capable of producing Detectable products of enzymes, radionuclides, biotoxins, cytokines (such as IL-2, etc.), antibodies, antibody Fc fragments, antibody scFv fragments, gold nanoparticles/nanorods, virus particles, liposomes, nanomagnetic particles , prodrug-activating enzymes (eg, DT-diaphorase (DTD) or biphenylhydrolase-like protein (BPHL)), or nanoparticles in any form.
- DTD DT-diaphorase
- BPHL biphenylhydrolase-like protein
- the eighth aspect of the present invention provides a multispecific antibody, said multispecific antibody comprising: the anti-TSLP nanobody of the first aspect of the present invention, or the anti-TSLP antibody of the second aspect of the present invention.
- the multispecific antibody further comprises an Fc segment of the antibody.
- the ninth aspect of the present invention provides a recombinant protein, which has:
- the tag sequence includes Fc tag, HA tag and 6His tag.
- the recombinant protein specifically binds to TSLP protein.
- the tenth aspect of the present invention provides a pharmaceutical composition, which contains:
- the coupling moiety of the immunoconjugate is a drug, a toxin, and/or a therapeutic isotope.
- the pharmaceutical composition also contains other drugs for treating immune system diseases or tumor diseases.
- the other drugs for treating immune system diseases or tumor diseases are selected from the group consisting of budesonide, fluticasone, beclomethasone, mometasone furoate, salbutamol, theophylline, formoterol, Tiotropium bromide, sulfasalazine, methotrexate, cyclophosphamide, fluorouracil, bleomycin, anastrozole, or a combination thereof.
- the pharmaceutical composition is used to prepare medicines for preventing and/or treating diseases or diseases related to TSLP.
- the diseases or conditions related to TSLP include immune system diseases or tumor diseases.
- the immune system disease is selected from the group consisting of asthma, atopic dermatitis, chronic obstructive pulmonary disease (COPD), allergic conjunctivitis, food allergy, ulcerative colitis, Crohn's disease , rhinitis, ankylosing spondylitis, systemic lupus erythematosus, rheumatoid arthritis, hypersensitivity pneumonitis, allergic granulomatous vasculitis, nasal polyposis, or combinations thereof.
- COPD chronic obstructive pulmonary disease
- the tumor disease is selected from the group consisting of breast cancer, pancreatic cancer, cervical cancer, multiple myeloma, colorectal cancer, lung cancer, thyroid cancer, ovarian cancer, liver cancer, or a combination thereof.
- the eleventh aspect of the present invention provides the anti-TSLP nanobody described in the first aspect of the present invention, the anti-TSLP antibody described in the second aspect of the present invention, the immunoconjugate as described in the seventh aspect of the present invention, or the anti-TSLP nanobody described in the seventh aspect of the present invention.
- the use of the multispecific antibody described in the eighth aspect or the recombinant protein described in the ninth aspect of the present invention or the pharmaceutical composition described in the tenth aspect of the present invention (a) for the preparation of prevention and/or treatment of TSLP-related Drugs for diseases; and/or (b) preparation of reagents, detection plates or kits for detecting TSLP.
- the diseases or conditions related to TSLP include immune system diseases or tumor diseases.
- the immune system disease is selected from the group consisting of asthma, atopic dermatitis, chronic obstructive pulmonary disease (COPD), allergic conjunctivitis, food allergy, ulcerative colitis, Crohn's disease , rhinitis, ankylosing spondylitis, systemic lupus erythematosus, rheumatoid arthritis, hypersensitivity pneumonitis, allergic granulomatous vasculitis, nasal polyposis, or combinations thereof.
- COPD chronic obstructive pulmonary disease
- the tumor disease is selected from the group consisting of breast cancer, pancreatic cancer, cervical cancer, multiple myeloma, colorectal cancer, lung cancer, thyroid cancer, ovarian cancer, liver cancer, or a combination thereof.
- the TSLP is human TSLP.
- the indicated reagent is a diagnostic reagent.
- the diagnostic reagent shown is a contrast agent
- the reagent is used to detect TSLP protein or fragments thereof in a sample.
- the detection includes flow detection and cell immunofluorescence detection.
- the use is diagnostic and/or non-diagnostic, and/or therapeutic and/or non-therapeutic.
- the twelfth aspect of the present invention provides a method for detecting TSLP protein in a sample, the method comprising the steps of:
- the method is a non-diagnostic and non-therapeutic method.
- the thirteenth aspect of the present invention provides a TSLP protein detection reagent, said detection reagent comprising:
- the coupling moiety of the immunoconjugate is an isotope for diagnosis.
- the detection-acceptable carrier is a non-toxic, inert aqueous carrier medium.
- the detection reagent is one or more reagents selected from the group consisting of isotopic tracers, contrast agents, flow detection reagents, cellular immunofluorescence detection reagents, magnetic nanoparticles and imaging agent.
- the detection reagent is used for in vivo detection.
- the dosage form of the detection reagent is liquid or powder (such as aqueous solution, injection, freeze-dried powder, tablet, buccal preparation, aerosol).
- the fourteenth aspect of the present invention provides a kit for detecting TSLP protein, which contains the immunoconjugate according to the seventh aspect of the present invention or the detection reagent according to the thirteenth aspect of the present invention, and instructions.
- the instructions describe that the kit is used to non-invasively detect the expression of TSLP in the subject.
- the fifteenth aspect of the present invention provides the use of the immunoconjugate described in the seventh aspect of the present invention for preparing a contrast agent for detecting TSLP protein in vivo.
- the detection is used for the diagnosis or prognosis of diseases or diseases related to TSLP.
- the sixteenth aspect of the present invention provides a method for treating diseases, the method comprising: administering the anti-TSLP nanobody described in the first aspect of the present invention, the anti-TSLP antibody described in the second aspect of the present invention, The immunoconjugate according to the seventh aspect of the present invention or the multispecific antibody according to the eighth aspect of the present invention or the recombinant protein according to the ninth aspect of the present invention or the pharmaceutical composition according to the tenth aspect of the present invention.
- the subject includes a human or a non-human mammal.
- non-human mammals include rodents (such as mice, rabbits), and non-human primates (such as monkeys).
- Figure 1A and Figure 1B are the results of flow cytometry blocking activity detection of 31 candidate antibodies. The results showed that the blocking activity of 14 antibodies among the 31 candidate antibodies was significantly better than that of the control antibody Tezepelumab.
- Fig. 2 is the detection result of binding kinetics of 14 strains of blocking TSLP nanobodies.
- Figure 3 is the SDS-PAGE results of the shake flask expression supernatants of bivalent single domain antibodies Bi-HuNb5-31, Bi-HuNb7-54, and Bi-HuNb10-63 in Pichia pastoris, and the yields are 475ug/mL and 310ug respectively /mL, 510ug/mL.
- Fig. 4 is the result of detecting the blocking activity of the humanized bivalent antibody by ELISA. The results showed that the blocking activity of the three humanized bivalent antibodies was significantly better than that of the control antibody Tezepelumab.
- Fig. 5 is the results of the inhibitory effect of the humanized bivalent antibody on the proliferation of BaF3/TSLPR-IL7R cells. The results showed that the inhibitory effect of two humanized antibodies on the pSTAT5 signaling pathway in BaF3/TSLPR-IL7R cells was better than that of the control antibody Tezepelumab.
- a class of anti-TSLP nanobody was unexpectedly discovered for the first time, and the experimental results showed that the nanobody of the present invention can effectively block the interaction between TSLP and TSLPR, and the blocking activity is significantly better than that of the control antibody Tezepelumab; the nanobody of the present invention can effectively inhibit The inhibitory activity of the Baf3/TSLPR-IL7R cell proliferation is better than that of the control antibody Tezepelumab; the expression yield of the nanobody of the present invention in Pichia pastoris can reach 17-23g/L, which is significantly higher than the industry level. On this basis, the present inventors have completed the present invention.
- Nanobody of the invention As used herein, the terms “Nanobody of the invention”, “Nanobody of the invention”, “anti-TSLP Nanobody of the invention”, “TSLP Nanobody of the invention”, “anti-TSLP Nanobody”, “TSLP Nanobody” Having the same meaning and being used interchangeably, both refer to Nanobodies that specifically recognize and bind to TSLP (including human TSLP).
- antibody or "immunoglobulin” is a heterotetrameric protein of about 150,000 Daltons with identical structural features, consisting of two identical light (L) chains and two identical heavy chains (H) Composition. Each light chain is linked to a heavy chain by one covalent disulfide bond, and the number of disulfide bonds varies between heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has a variable region (VH) at one end followed by constant regions.
- VH variable region
- Each light chain has a variable region (VL) at one end and a constant region at the other end; the constant region of the light chain is opposite the first constant region of the heavy chain, and the variable region of the light chain is opposite the variable region of the heavy chain .
- VL variable region
- Specific amino acid residues form the interface between the variable domains of the light and heavy chains.
- the terms “single domain”, “VHH”, “nanobody”, “heavy chain antibody” (single domain antibody, sdAb, or nanobody nanobody) have the same meaning and are used interchangeably, referring to Cloning the variable region of the antibody heavy chain to construct a Nanobody (VHH) consisting of only one heavy chain variable region, which is the smallest antigen-binding fragment with full functionality.
- VHH Single domain antibody
- sdAb single domain antibody, sdAb, or nanobody nanobody
- variable means that certain portions of the variable regions among antibodies differ in sequence, which contribute to the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout antibody variable domains. It is concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions in the light and heavy chain variable regions. The more conserved portions of the variable domains are called the framework regions (FR).
- CDRs complementarity determining regions
- FR framework regions
- the variable domains of native heavy and light chains each contain four FR regions in a roughly b-sheet configuration connected by three CDRs that form connecting loops, which in some cases may form partial b-sheet structures.
- the CDRs in each chain are in close proximity through the FR regions and together with the CDRs of the other chain form the antigen-binding site of the antibody (see Kabat et al., NIH Publ. No. 91-3242, Vol. I, pp. 647-669 (1991)).
- the constant regions are not directly involved in the binding of the antibody to the antigen, but they exhibit different effector functions, for example involved in the antibody-dependent cytotoxicity of the antibody.
- immunoconjugates and fusion expression products include: drugs, toxins, cytokines (cytokine), radionuclides, enzymes and other diagnostic or therapeutic molecules combined with antibodies or fragments thereof of the present invention to form of conjugates.
- the present invention also includes cell surface markers or antigens that bind to the anti-TSLP antibody or fragment thereof.
- variable region and “complementarity determining region (CDR)” are used interchangeably.
- the heavy chain variable region of the antibody includes three complementarity determining regions CDR1, CDR2, and CDR3.
- the heavy chain of the antibody includes the above-mentioned heavy chain variable region and heavy chain constant region.
- antibody of the present invention protein of the present invention
- polypeptide of the present invention are used interchangeably, and all refer to polypeptides that specifically bind to TSLP proteins, such as proteins or polypeptides with heavy chain variable regions . They may or may not contain starting methionine.
- the invention also provides other proteins or fusion expression products having the antibodies of the invention.
- the present invention includes any protein or protein conjugates and fusion expression products (i.e., immunoconjugates and fusion expression products) having a heavy chain containing a variable region, as long as the variable region is compatible with the heavy chain of the antibody of the present invention
- the variable regions are identical or at least 90% homologous, preferably at least 95% homologous.
- the antigen-binding properties of an antibody can be described by three specific regions located in the variable region of the heavy chain, called the variable region (CDR), which is separated into four framework regions (FR), four FR amino acids
- CDR variable region
- FR framework regions
- the sequence is relatively conservative and does not directly participate in the binding reaction.
- CDRs form a ring structure, and the ⁇ sheets formed by the FRs in between are close to each other in the spatial structure.
- the CDRs on the heavy chain and the corresponding CDRs on the light chain constitute the antigen-binding site of the antibody.
- Which amino acids constitute FR or CDR regions can be determined by comparing the amino acid sequences of antibodies of the same type.
- variable regions of the heavy chains of the antibodies of the invention are of particular interest because at least some of them are involved in binding antigen. Therefore, the present invention includes those molecules having antibody heavy chain variable regions with CDRs, as long as the CDRs have more than 90% (preferably more than 95%, most preferably more than 98%) homology to the CDRs identified herein sex.
- the present invention includes not only complete antibodies, but also fragments of antibodies with immunological activity or fusion proteins formed by antibodies and other sequences. Accordingly, the invention also includes fragments, derivatives and analogs of said antibodies.
- fragment refers to a polypeptide that substantially retains the same biological function or activity of the antibody of the present invention.
- the polypeptide fragments, derivatives or analogs of the present invention may be (i) polypeptides having one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) substituted, and such substituted amino acid residues It may or may not be encoded by the genetic code, or (ii) a polypeptide having a substituent group in one or more amino acid residues, or (iii) a mature polypeptide in combination with another compound (such as a compound that extends the half-life of the polypeptide, e.g.
- polyethylene glycol polyethylene glycol
- an additional amino acid sequence fused to the polypeptide sequence such as a leader sequence or secretory sequence or a sequence or proprotein sequence used to purify the polypeptide, or with fusion protein formed by 6His tag.
- an additional amino acid sequence fused to the polypeptide sequence such as a leader sequence or secretory sequence or a sequence or proprotein sequence used to purify the polypeptide, or with fusion protein formed by 6His tag.
- the antibody of the present invention refers to a polypeptide that has TSLP binding activity and includes the above-mentioned CDR region.
- the term also includes variant forms of polypeptides comprising the above CDR regions that have the same function as the antibodies of the present invention. These variations include (but are not limited to): one or more (usually 1-50, preferably 1-30, more preferably 1-20, and most preferably 1-10) amino acid deletions , insertion and/or substitution, and addition of one or several (usually within 20, preferably within 10, more preferably within 5) amino acids at the C-terminal and/or N-terminal.
- substitutions with amino acids with similar or similar properties generally do not change the function of the protein.
- adding one or several amino acids at the C-terminus and/or N-terminus usually does not change the function of the protein.
- the term also includes active fragments and active derivatives of the antibodies of the invention.
- Variants of the polypeptide include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, DNA hybrids that can hybridize with the DNA encoding the antibody of the present invention under high or low stringency conditions
- the encoded protein, and the polypeptide or protein obtained by using the antiserum against the antibody of the present invention.
- the invention also provides other polypeptides, such as fusion proteins comprising Nanobodies or fragments thereof.
- the invention also includes fragments of the Nanobodies of the invention.
- the fragment has at least about 50 contiguous amino acids, preferably at least about 50 contiguous amino acids, more preferably at least about 80 contiguous amino acids, and most preferably at least about 100 contiguous amino acids of an antibody of the invention.
- “conservative variants of the antibody of the present invention” refer to at most 10, preferably at most 8, more preferably at most 5, and most preferably at most 3 amino acid sequences compared with the amino acid sequence of the antibody of the present invention.
- An amino acid is replaced by an amino acid with similar or similar properties to form a polypeptide.
- These conservative variant polypeptides are preferably produced by amino acid substitutions according to Table A.
- the present invention also provides polynucleotide molecules encoding the above-mentioned antibodies or fragments or fusion proteins thereof.
- a polynucleotide of the invention may be in the form of DNA or RNA.
- Forms of DNA include cDNA, genomic DNA or synthetic DNA.
- DNA can be single-stranded or double-stranded.
- DNA can be either the coding strand or the non-coding strand.
- a polynucleotide encoding a mature polypeptide of the present invention includes: a coding sequence that encodes only the mature polypeptide; a coding sequence for the mature polypeptide and various additional coding sequences; a coding sequence for the mature polypeptide (and optional additional coding sequences) and non-coding sequences .
- polynucleotide encoding a polypeptide may include a polynucleotide encoding the polypeptide, or may also include additional coding and/or non-coding sequences.
- the present invention also relates to polynucleotides which hybridize to the above-mentioned sequences and which have at least 50%, preferably at least 70%, more preferably at least 80% identity between the two sequences.
- the invention particularly relates to polynucleotides which are hybridizable under stringent conditions to the polynucleotides of the invention.
- stringent conditions refers to: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2 ⁇ SSC, 0.1% SDS, 60°C; or (2) hybridization with There are denaturing agents, such as 50% (v/v) formamide, 0.1% calf serum/0.1% Ficoll, 42°C, etc.; or (3) the identity between the two sequences is at least 90%, more Preferably, hybridization occurs above 95%.
- the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide.
- the full-length nucleotide sequence of the antibody of the present invention or its fragments can usually be obtained by PCR amplification, recombination or artificial synthesis.
- a feasible method is to use artificial synthesis to synthesize related sequences, especially when the fragment length is short. Often, fragments with very long sequences are obtained by synthesizing multiple small fragments and then ligating them.
- the coding sequence of the heavy chain and an expression tag (such as 6His) can also be fused together to form a fusion protein.
- biomolecules nucleic acid, protein, etc.
- the biomolecules involved in the present invention include biomolecules in an isolated form.
- the DNA sequence encoding the protein of the present invention (or its fragment, or its derivative) can be obtained completely through chemical synthesis. This DNA sequence can then be introduced into various existing DNA molecules (or eg vectors) and cells known in the art. In addition, mutations can also be introduced into the protein sequences of the invention by chemical synthesis.
- the present invention also relates to vectors comprising the above-mentioned appropriate DNA sequences and appropriate promoter or control sequences. These vectors can be used to transform appropriate host cells so that they express the protein.
- the host cell may be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell.
- a prokaryotic cell such as a bacterial cell
- a lower eukaryotic cell such as a yeast cell
- a higher eukaryotic cell such as a mammalian cell.
- Representative examples are: Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast; insect cells of Drosophila S2 or Sf9; animal cells of CHO, COS7, 293 cells, etc.
- Transformation of host cells with recombinant DNA can be performed using conventional techniques well known to those skilled in the art.
- competent cells capable of taking up DNA can be harvested after the exponential growth phase and treated with the CaCl2 method using procedures well known in the art. Another method is to use MgCl2 . Transformation can also be performed by electroporation, if desired.
- DNA transfection methods can be used: calcium phosphate co-precipitation method, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.
- the obtained transformant can be cultured by conventional methods to express the polypeptide encoded by the gene of the present invention.
- the medium used in the culture can be selected from various conventional media according to the host cells used.
- the culture is carried out under conditions suitable for the growth of the host cells. After the host cells have grown to an appropriate cell density, the selected promoter is induced by an appropriate method (such as temperature shift or chemical induction), and the cells are cultured for an additional period of time.
- the recombinant polypeptide in the above method can be expressed inside the cell, or on the cell membrane, or secreted outside the cell.
- the recombinant protein can be isolated and purified by various separation methods by taking advantage of its physical, chemical and other properties, if desired. These methods are well known to those skilled in the art. Examples of these methods include, but are not limited to: conventional refolding treatment, treatment with protein precipitating agents (salting out method), centrifugation, osmotic disruption, supertreatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption layer Analysis, ion exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods.
- the antibodies of the invention can be used alone, or combined or conjugated with a detectable label (for diagnostic purposes), a therapeutic agent, a PK (protein kinase) modifying moiety, or a combination of any of these.
- Detectable labels for diagnostic purposes include, but are not limited to, fluorescent or luminescent labels, radioactive labels, MRI (magnetic resonance imaging) or CT (computed tomography) contrast agents, or substances capable of producing a detectable product. enzyme.
- Therapeutic agents that can be combined or coupled with the antibody of the present invention include but are not limited to: 1. Radionuclide; 2. Biological toxicity; 3. Cytokines such as IL-2, etc.; 4. Gold nanoparticles/nanorods; 5. Viruses Particles; 6. Liposomes; 7. Nanomagnetic particles; 8. Prodrug activating enzymes (for example, DT-diaphorase (DTD) or biphenylhydrolase-like protein (BPHL)), etc.
- DTD DT-diaphorase
- BPHL biphenylhydrolase-like protein
- Thymic stromal lymphopoietin TSLP
- Thymic stromal lymphopoietin is a short-chain cytokine with a four-helix bundle structure and belongs to the IL-2 cytokine family.
- TSLP is commonly expressed in epithelial cells lining the lung, skin, and intestinal barrier surfaces.
- Animal experiments showed that TSLP was highly expressed in the lungs of allergen-induced asthma model mice, while TSLP receptor-deficient mice showed significantly reduced asthma, and lung-specific TSLP transgenic mice showed Th2-type inflammation and increased IgE airway inflammation and highly reactive. Further studies suggest that TSLP activates bone marrow-derived dendritic cells and upregulates co-stimulatory molecules to produce Th2-type cell chemokine CCL17.
- TSLP is an important factor and necessary condition for initiating airway allergic inflammation. It is an upstream regulator of multiple inflammatory pathways in various diseases, including asthma, and is critical for the initiation and persistence of airway inflammation.
- TSLP is also a cytokine related to the pathogenesis of atopic dermatitis (AD). What's more, researchers have found that in different types of tumors, TSLP levels are increased, and TSLP can induce tumor cells to express another protein called BCL-2, which can protect tumors from death. . TSLP is therefore also crucial for tumor survival.
- TSLPR Thymic stromal lymphopoietin receptor
- TSLPR receptors are type I transmembrane proteins and belong to the hematopoietic cytokine receptor family.
- a functional TSLPR complex is composed of TSLPR and IL-7Ra.
- TSLPR is also known as cytokine receptor-like molecule 2 or type I cytokine receptor ⁇ 1.
- TSLP initiates intracellular type 2 signaling by binding to its high-affinity heterodimeric receptor complex consisting of its specific receptor TSLPR, which interacts with IL-2, IL-4, IL
- TSLPR specific receptor
- IL-2 IL-2
- IL-4 IL-4
- IL-7R ⁇ subunit in cells that co-express TSLPR and IL-7R ⁇ (CD127).
- TSLP initially binds to TSLPR and subsequently recruits the IL-7R ⁇ chain.
- the present invention also provides a composition.
- the composition is a pharmaceutical composition, which contains the above-mentioned antibody or its active fragment or its fusion protein, and a pharmaceutically acceptable carrier.
- these materials can be formulated in a non-toxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is usually about 5-8, preferably about 6-8, although the pH value can be changed according to the Depending on the nature of the substance formulated and the condition to be treated.
- the formulated pharmaceutical composition can be administered by conventional routes, including but not limited to: intraperitoneal, intravenous, or topical administration.
- the pharmaceutical composition of the present invention can be directly used to bind TSLP protein molecules, and thus can be used to treat diseases or disorders related to TSLP (including immune system diseases or tumor diseases).
- diseases or disorders related to TSLP including immune system diseases or tumor diseases.
- other therapeutic agents may also be used concomitantly.
- the pharmaceutical composition of the present invention contains a safe and effective amount (such as 0.001-99wt%, preferably 0.01-90wt%, more preferably 0.1-80wt%) of the above-mentioned Nanobody (or its conjugate) of the present invention and pharmaceutically acceptable carrier or excipient.
- Such carriers include, but are not limited to: saline, buffer, dextrose, water, glycerol, ethanol, and combinations thereof.
- the pharmaceutical formulation should match the mode of administration.
- the pharmaceutical composition of the present invention can be prepared in the form of injection, for example, by conventional methods using physiological saline or aqueous solution containing glucose and other adjuvants. Pharmaceutical compositions such as injections and solutions are preferably produced under sterile conditions.
- the active ingredient is administered in a therapeutically effective amount, for example about 10 micrograms/kg body weight to about 50 mg/kg body weight per day.
- the polypeptides of the invention can also be used with other therapeutic agents.
- a safe and effective amount of the immunoconjugate is administered to the mammal, wherein the safe and effective amount is usually at least about 10 micrograms/kg body weight, and in most cases no more than about 50 mg/kg body weight, Preferably the dose is about 10 micrograms/kg body weight to about 10 mg/kg body weight.
- the route of administration and the health status of the patient should also be considered for the specific dosage, which are within the skill of skilled physicians.
- amino acid sequence of the VHH chain of the anti-TSLP nanobody is selected from SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:34 or SEQ ID One or more of NO:38.
- the anti-TSLP nanobody includes a monomer, a bivalent body (bivalent antibody), a tetravalent body (tetravalent antibody), and/or a multivalent body (multivalent antibody).
- the anti-TSLP nanobody comprises two compounds having the following characteristics such as SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 34 or SEQ ID NO: 38
- SEQ ID NO: 8 SEQ ID NO: 12
- SEQ ID NO: 21 SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 34 or SEQ ID NO: 38
- VHH chains are linked by linking peptides.
- sequence of the connecting peptide is GGGGSGGGGSGGGGSGGGGS.
- the Nanobody has a detectable label. More preferably, the label is selected from the group consisting of isotopes, colloidal gold labels, colored labels or fluorescent labels.
- colloidal gold labeling can be performed using methods known to those skilled in the art.
- the nanobody of TSLP is labeled with colloidal gold to obtain a nanobody labeled with colloidal gold.
- the present invention also relates to methods for detecting TSLP proteins.
- the steps of the method are roughly as follows: obtain a cell and/or tissue sample; dissolve the sample in a medium; detect the level of TSLP protein in the dissolved sample.
- the sample used is not particularly limited, and a representative example is a cell-containing sample present in a cell preservation solution.
- the present invention also provides a kit containing the antibody (or its fragment) or detection plate of the present invention.
- the kit further includes a container, instructions for use, buffer and the like.
- the present invention also provides a detection kit for detecting the level of TSLP, which includes an antibody for recognizing TSLP protein, a lysis medium for dissolving samples, general reagents and buffers required for detection, such as various buffers, detection labeling, detection substrates, etc.
- the test kit may be an in vitro diagnostic device.
- the nanobody of the present invention has a wide range of biological and clinical application values, and its application involves the diagnosis and treatment of diseases or diseases related to TSLP, basic medical research, biological research and other fields.
- a preferred application is for clinical diagnosis and targeted therapy against TSLP.
- Nanobody of the present invention can effectively block the interaction between TSLP and TSLPR.
- the nanobody of the present invention has stronger blocking activity.
- the nanobody of the present invention can be expressed in Pichia pastoris, the expression yield of the shake flask is relatively high, and the yield of the fermenter can reach 17-23g/L.
- human TSLP protein was purified after transfection into HEK293F cells.
- human TSLP protein was purified after transfection into HEK293F cells.
- four Xinjiang Bactrian camels were immunized, once a week, and peripheral blood was collected after seven times of immunization, RNA was isolated and VHH gene fragment was amplified, and then cloned into pMECS vector, Electroporation into TG1 competent cells to establish a high-quality phage display nanobody library. After testing, the storage capacity of the four libraries all reached above 1x10 9 CFU, and the fragment insertion rate was above 80%.
- Nanobody clones with different sequences above were inoculated in TB medium and induced overnight with IPTG, and the supernatant was collected by lysing the cells for blocking activity detection.
- the cultured CHOZEN/TSLPR stably transfected cells were divided into 96-well plates, with 3E5 cells per well, centrifuged at 3000rpm for 3 minutes to remove the supernatant, and the lysate of each antibody and TSLP-Biotin protein were added to incubate for 20 minutes. Discard the supernatant by centrifugation, add diluted SA-PE antibody, and incubate at 4°C for 20min.
- the above 31 purified antibodies were tested for blocking activity by flow cytometry again. Aliquot the cultured HEK293F/TSLPR transient cells into a 96-well plate, 3E5 cells per well, centrifuge at 3000rpm for 3min to remove the supernatant, and add the diluted antibodies (2-fold serial dilution starting from 20ug/mL) And TSLP-Biotin protein incubation for 20min. In this experiment, Tezepelumab was used as the control antibody. Then centrifuge the supernatant, add diluted SA-PE antibody, and incubate at 4°C for 20min.
- the binding kinetics of 14 blocking TSLP nanobodies were detected by bio-layer interferometry (BLI).
- the candidate antibody was diluted to 5ug/mL with PBST buffer, and the TSLP-Fc antigen was diluted 2 times with PBST buffer for six concentration gradients (2 times serial dilution starting from 20nM), and the operating conditions of the instrument were set: temperature 30°C, Shake speed 1000rpm.
- the protein A-coated probe was used to capture the antibody, the capture time was 60s; the binding time was 240s to the antigen diluted in gradient; the dissociation time was 300s; 10mM glycine (pH1.7) was regenerated twice, each 5s.
- Fortebio Analysis version 9.0 was used for analysis, the Global mode was used for fitting, and the association rate (Kon), dissociation rate (Kdis) and dissociation constant KD were calculated. The result is shown in Figure 2.
- the above humanized antibody was constructed into a bivalent form, connected by a linker (G 4 S)4, and the sequence after connection is shown in SEQ ID NO.:40, SEQ ID NO.:41 and SEQ ID NO.:42 , followed by expression in Pichia pastoris.
- the expression method is as follows: (1) construct the above TSLP nanobody bivalent sequence into pPICZaA vector; (2) electrotransform into X-33 competent cells after linearization with Sac I restriction endonuclease; ( 3) Spread the electroporated samples on the YPD plate medium containing different concentrations of bleomycin resistance, and culture them in a 30°C incubator for 3-4 days; After cloning, pick single clones on plates with different concentrations and place them in BMGY medium.
- the above purified bivalent humanized antibody was subjected to ELISA to detect blocking activity.
- For good antibody samples add 50uL 0.02ug/mL biotinylated TSLPR protein to each well, and incubate at 37°C for 1 hour; after washing 5 times with PBST, add 100uL of SA-HRP (1:100000 dilution), and incubate at 37°C for 1 hour hours; after washing with PBST for 5 times, add 100uL of TMB color developing solution, develop color at 37°C for 10min, add 2M H 2 SO 4 50uL/well to terminate the reaction, and measure the absorbance at a wavelength of 450nm with a microplate
- Well-grown BaF3/TSLPR-IL7R cells were centrifuged at 1000rpm for 5min, resuspended in PBS, and distributed into 96-well plates at 1x105 cell wells per well.
- Mix 25uL diluted human TSLP factor with serially diluted bivalent humanized antibody or Tezepelumab incubate at 37°C for 30 minutes, then add the mixture to the cells at 37°C, 5% CO 2 for 20 minutes. After washing the cells with PBS, add formaldehyde to fix them, and then add pre-cooled methanol to incubate for 10 minutes. Finally, an anti-phosphorylated STAT5-PE-labeled antibody was added and incubated for 30 minutes.
- the expression strains of the above three antibodies, Glycerol bacteria were respectively amplified and cultivated as primary seeds at a ratio of 1:100, and then transferred to fresh medium for secondary seed cultivation. After the secondary seed culture was qualified, they were placed in a 7L fermenter for fermentation For cultivation, ammonia water was added automatically to adjust the pH of the fermentation culture to 6.0. During the cultivation process, regular samples were taken to detect the pH of the fermentation broth, the wet weight of the bacteria, the OD value of the bacteria solution, etc., and the stirring speed, tank pressure and oxygen ventilation were adjusted according to the change of dissolved oxygen. According to the wet weight of fermentation cells and the change of dissolved oxygen, glycerol feed medium and methanol feed medium were added at different stages of fermentation culture.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Description
最初的残基 | 代表性的取代 | 优选的取代 |
Ala(A) | Val;Leu;Ile | Val |
Arg(R) | Lys;Gln;Asn | Lys |
Asn(N) | Gln;His;Lys;Arg | Gln |
Asp(D) | Glu | Glu |
Cys(C) | Ser | Ser |
Gln(Q) | Asn | Asn |
Glu(E) | Asp | Asp |
Gly(G) | Pro;Ala | Ala |
His(H) | Asn;Gln;Lys;Arg | Arg |
Ile(I) | Leu;Val;Met;Ala;Phe | Leu |
Leu(L) | Ile;Val;Met;Ala;Phe | Ile |
Lys(K) | Arg;Gln;Asn | Arg |
Met(M) | Leu;Phe;Ile | Leu |
Phe(F) | Leu;Val;Ile;Ala;Tyr | Leu |
Pro(P) | Ala | Ala |
Ser(S) | Thr | Thr |
Thr(T) | Ser | Ser |
Trp(W) | Tyr;Phe | Tyr |
Tyr(Y) | Trp;Phe;Thr;Ser | Phe |
Val(V) | Ile;Leu;Met;Phe;Ala | Leu |
Claims (19)
- 一种抗TSLP纳米抗体,其特征在于,所述纳米抗体中的VHH链的互补决定区CDR区为选自下组的一种或多种:(1)SEQ ID NO:1所示的CDR1、SEQ ID NO:2所示的CDR2、和SEQ ID NO:3所示的CDR3;(2)SEQ ID NO:14所示的CDR1、SEQ ID NO:15所示的CDR2、和SEQ ID NO:16所示的CDR3;和(3)SEQ ID NO:27所示的CDR1、SEQ ID NO:28所示的CDR2、和SEQ ID NO:29所示的CDR3。
- 如权利要求1所述的抗TSLP纳米抗体,其特征在于,所述抗TSLP纳米抗体的VHH链还包括框架区FR,所述的框架区FR为选自下组的一种或多种:(1)SEQ ID NO:4所示的FR1、SEQ ID NO:5所示的FR2、SEQ ID NO:6所示的FR3、和SEQ ID NO:7所示的FR4;(2)SEQ ID NO:10所示的FR1、SEQ ID NO:5所示的FR2、SEQ ID NO:6所示的FR3、和SEQ ID NO:11所示的FR4;(3)SEQ ID NO:17所示的FR1、SEQ ID NO:18所示的FR2、SEQ ID NO:19所示的FR3、和SEQ ID NO:20所示的FR4;(4)SEQ ID NO:23所示的FR1、SEQ ID NO:18所示的FR2、SEQ ID NO:19所示的FR3、和SEQ ID NO:24所示的FR4;(5)SEQ ID NO:30所示的FR1、SEQ ID NO:31所示的FR2、SEQ ID NO:32所示的FR3、和SEQ ID NO:33所示的FR4;和(6)SEQ ID NO:36所示的FR1、SEQ ID NO:31所示的FR2、SEQ ID NO:32所示的FR3、和SEQ ID NO:37所示的FR4。
- 如权利要求1所述的抗TSLP纳米抗体,其特征在于,所述抗TSLP纳米抗体的VHH链的氨基酸序列选自下组:SEQ ID NO:8、SEQ ID NO:12、SEQ ID NO:21、SEQ ID NO:25、SEQ ID NO:34、SEQ ID NO:38、或其组合。
- 一种抗TSLP抗体,其特征在于,它是针对TSLP表位的抗体,并且具有权利要求1所述的抗TSLP纳米抗体。
- 一种抗TSLP抗体,其特征在于,所述抗体包括一个或多个如权利要求 1所述的抗TSLP纳米抗体。
- 如权利要求4或5所述的抗体,其特征在于,所述抗体包括单体、二价抗体、和/或多价抗体。
- 一种多核苷酸,其特征在于,所述多核苷酸编码选自下组的蛋白质:权利要求1所述的抗TSLP纳米抗体、权利要求4所述的抗TSLP抗体或权利要求5所述的抗TSLP抗体。
- 一种表达载体,其特征在于,所述表达载体含有权利要求7所述的多核苷酸。
- 一种宿主细胞,其特征在于,所述宿主细胞含有权利要求8所述的表达载体,或其基因组中整合有权利要求7所述的多核苷酸。
- 一种产生抗TSLP纳米抗体的方法,其特征在于,包括步骤:(a)在适合产生纳米抗体的条件下,培养权利要求9所述的宿主细胞,从而获得含所述抗TSLP纳米抗体的培养物;(b)从所述培养物中分离或回收所述的抗TSLP纳米抗体;以及(c)任选地,纯化和/或修饰得步骤(b)中获得的抗TSLP纳米抗体。
- 一种免疫偶联物,其特征在于,该免疫偶联物含有:(a)权利要求1所述的抗TSLP纳米抗体、权利要求4所述的抗TSLP抗体或权利要求5所述的抗TSLP抗体;和(b)选自下组的偶联部分:可检测标记物、药物、毒素、细胞因子、放射性核素、酶、金纳米颗粒/纳米棒、纳米磁粒、病毒外壳蛋白或VLP、或其组合。
- 一种多特异性抗体,其特征在于,所述的多特异性抗体包含:权利要求1所述的抗TSLP纳米抗体、权利要求4所述的抗TSLP抗体或权利要求5所述的抗TSLP抗体。
- 一种重组蛋白,其特征在于,所述的重组蛋白具有:(i)如权利要求1所述的抗TSLP纳米抗体、权利要求4所述的抗TSLP抗体或权利要求5所述的抗TSLP抗体;以及(ii)任选的协助表达和/或纯化的标签序列。
- 一种药物组合物,其特征在于,所述药物组合物含有:(i)权利要求1所述的抗TSLP纳米抗体、权利要求4所述的抗TSLP抗体或权利要求5所述的抗TSLP抗体、或权利要求11所述的免疫偶联物或权利要求12所述的多特异性抗体或权利要求13所述的重组蛋白;以及(ii)药学上可接受的载体。
- 权利要求1所述的抗TSLP纳米抗体、权利要求4所述的抗TSLP抗体或权利要求5所述的抗TSLP抗体、如权利要求11所述的免疫偶联物或权利要求12所述的多特异性抗体或权利要求13所述的重组蛋白或权利要求14所述的药物 组合物的用途;其特征在于,(a)用于制备预防和/或治疗与TSLP相关的疾病的药物;和/或(b)用于制备检测TSLP的试剂、检测板或试剂盒。
- 一种检测样品中TSLP蛋白的方法,其特征在于,所述方法包括步骤:(1)将样品与权利要求1所述的抗TSLP纳米抗体、权利要求4所述的抗TSLP抗体或权利要求5所述的抗TSLP抗体、或权利要求11所述的免疫偶联物或权利要求12所述的多特异性抗体或权利要求13所述的重组蛋白接触;(2)检测是否形成抗原-抗体复合物,其中形成复合物就表示样品中存在TSLP蛋白。
- 一种TSLP蛋白检测试剂,其特征在于,所述的检测试剂包含:(i)权利要求1所述的抗TSLP纳米抗体、权利要求4所述的抗TSLP抗体或权利要求5所述的抗TSLP抗体、或权利要求11所述的免疫偶联物或权利要求12所述的多特异性抗体或权利要求13所述的重组蛋白;以及(ii)检测学上可接受的载体。
- 一种检测TSLP蛋白的试剂盒,其特征在于,所述试剂盒含有权利要求7所述的免疫偶联物或权利要求17所述的检测试剂,以及说明书。
- 一种权利要求11所述的免疫偶联物的用途,其特征在于,用于制备体内检测TSLP蛋白的造影剂。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023540115A JP2024512858A (ja) | 2021-02-05 | 2022-05-16 | 抗tslpナノ抗体およびその使用 |
KR1020237025523A KR20230125042A (ko) | 2021-02-05 | 2022-05-16 | 항-tslp 나노항체 및 이의 응용 |
AU2022434181A AU2022434181A1 (en) | 2021-02-05 | 2022-05-16 | Anti-TSLP nanobodies and their applications |
CA3209675A CA3209675A1 (en) | 2021-02-05 | 2022-05-16 | Anti-tslp nanobodies and their applications |
EP22912783.2A EP4257605A1 (en) | 2021-02-05 | 2022-05-16 | Anti-tslp nanobody and use thereof |
IL303474A IL303474A (en) | 2021-02-05 | 2023-06-05 | Anti-TSLP nanoparticles and their use |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110164376 | 2021-02-05 | ||
CN202210111727.1 | 2022-01-26 | ||
CN202210111727.1A CN114853888B (zh) | 2021-02-05 | 2022-01-26 | 抗tslp纳米抗体及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023142309A1 true WO2023142309A1 (zh) | 2023-08-03 |
Family
ID=82627495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/093166 WO2023142309A1 (zh) | 2021-02-05 | 2022-05-16 | 抗tslp纳米抗体及其应用 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4257605A1 (zh) |
JP (1) | JP2024512858A (zh) |
KR (1) | KR20230125042A (zh) |
CN (1) | CN114853888B (zh) |
AU (1) | AU2022434181A1 (zh) |
CA (1) | CA3209675A1 (zh) |
IL (1) | IL303474A (zh) |
WO (1) | WO2023142309A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115850493B (zh) * | 2022-11-08 | 2024-03-12 | 江苏耀海生物制药有限公司 | 一种二价纳米抗体Cablivi的分离纯化方法 |
CN117551195B (zh) * | 2024-01-12 | 2024-04-09 | 杭州畅溪制药有限公司 | 靶向tslp的vhh纳米抗体及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107428828A (zh) * | 2015-03-11 | 2017-12-01 | 葛兰素史密斯克莱知识产权发展有限公司 | Tslp结合蛋白 |
CN110144011A (zh) | 2018-02-14 | 2019-08-20 | 上海洛启生物医药技术有限公司 | 针对t淋巴细胞免疫球蛋白黏蛋白3的单域抗体 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0603683D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
PT3031913T (pt) * | 2013-08-09 | 2019-05-31 | Astellas Pharma Inc | Novo anticorpo anti-receptor de tslp humana |
JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
-
2022
- 2022-01-26 CN CN202210111727.1A patent/CN114853888B/zh active Active
- 2022-05-16 JP JP2023540115A patent/JP2024512858A/ja active Pending
- 2022-05-16 CA CA3209675A patent/CA3209675A1/en active Pending
- 2022-05-16 WO PCT/CN2022/093166 patent/WO2023142309A1/zh active Application Filing
- 2022-05-16 EP EP22912783.2A patent/EP4257605A1/en active Pending
- 2022-05-16 AU AU2022434181A patent/AU2022434181A1/en active Pending
- 2022-05-16 KR KR1020237025523A patent/KR20230125042A/ko unknown
-
2023
- 2023-06-05 IL IL303474A patent/IL303474A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107428828A (zh) * | 2015-03-11 | 2017-12-01 | 葛兰素史密斯克莱知识产权发展有限公司 | Tslp结合蛋白 |
CN110144011A (zh) | 2018-02-14 | 2019-08-20 | 上海洛启生物医药技术有限公司 | 针对t淋巴细胞免疫球蛋白黏蛋白3的单域抗体 |
Non-Patent Citations (2)
Title |
---|
KABAT ET AL., NIH PUBL, no. 91-3242, 1991, pages 647 - 669 |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
Also Published As
Publication number | Publication date |
---|---|
CA3209675A1 (en) | 2023-08-03 |
IL303474A (en) | 2023-08-01 |
EP4257605A1 (en) | 2023-10-11 |
JP2024512858A (ja) | 2024-03-21 |
CN114853888A (zh) | 2022-08-05 |
AU2022434181A1 (en) | 2023-08-24 |
CN114853888B (zh) | 2023-11-03 |
KR20230125042A (ko) | 2023-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110452297B (zh) | 抗vegf单域抗体及其应用 | |
EP4238989A1 (en) | Anti-il5 nanoantibody and use thereof | |
WO2023142309A1 (zh) | 抗tslp纳米抗体及其应用 | |
JP7387206B2 (ja) | 抗il-4r単一ドメイン抗体およびその適用 | |
WO2023274365A1 (zh) | 抗trop2单域抗体及其应用 | |
WO2021047386A1 (zh) | 靶向caix抗原的纳米抗体及其应用 | |
WO2024099310A1 (zh) | 抗il-13长效纳米抗体序列及其应用 | |
WO2023020551A1 (zh) | 抗ptk7单域抗体及其应用 | |
WO2023116751A1 (zh) | 抗人血管生成素3纳米抗体及其应用 | |
WO2023133842A1 (zh) | 一种靶向IL-18Rβ的抗体及其应用 | |
CN118139893A (zh) | 抗ptk7单域抗体及其应用 | |
CN117186226A (zh) | 抗cd38纳米抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2023540115 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2022912783 Country of ref document: EP Effective date: 20230704 |
|
ENP | Entry into the national phase |
Ref document number: 20237025523 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023011535 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2022434181 Country of ref document: AU Date of ref document: 20220516 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3209675 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 112023011535 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230612 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11202305610T Country of ref document: SG |